Surgery yields excellent prognosis in pancreatic SPN

  • Pancreatology

  • curated by Jim Kling
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A single-center analysis reveals an excellent prognosis with surgery, even in the presence of liver metastases, among patients with solid pseudopapillary neoplasm of the pancreas (SPN).

Why this matters

  • Due to its rarity, the natural history of SPN has not been thoroughly studied.

Study design

  • Retrospective analysis of 243 cases at a single center (2 with synchronous liver metastases).
  • Funding: National Natural Science Foundation of China, Shanghai Sailing Program, National Science Foundation for Distinguished Young Scholars of China.

Key results

  • 74.5% of patients were female. Mean age, 35.3 years.
  • All patients underwent surgical resection, including pancreaticoduodenectomy (Whipple, 20.6%), pylorus-preserving pancreaticoduodenectomy (4.5%), distal pancreatectomy with splenectomy (52.3%), spleen-preserving distal pancreatectomy (9.1%), central pancreatectomy (6.6%), tumor enucleation (3.7%), total pancreatectomy resection (1.2%), and resection of retroperitoneum tumor (0.4%).
  • During a median follow-up of 46 (range, 10-118) months, 4 patients had a recurrence, which included the 2 subjects with liver metastases. 2 underwent reoperation, and 2 refused and later succumbed to tumor progression.
  • Survival was 100% at 1 year, 99.6% at 3 years, and 98.4% at 5 years.

Limitations

  • Single center.